SSAT058: Atripla to Eviplera Switch in Patients Without Central Nervous System Symptoms
NCT ID: NCT02529059
Last Updated: 2017-09-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
40 participants
INTERVENTIONAL
2015-11-30
2017-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study Title: SSAT 058 - A phase IV, open-label, multi centre pilot study to assess the prevalence of objective neurocognitive abnormality in patients without perceived Central Nervous System (CNS) symptoms on tenofovir/emtricitabine/efavirenz Atripla® and the effect of switching to a fixed dose combination of tenofovir/emtricitabine/rilpivirine (Eviplera®).
Proposed Sponsor: St Stephen's AIDS Trust
Chief Investigator: Dr Mark Nelson
Name of Investigational Product: Eviplera®
Name of Active Ingredients: Rilpivirine, tenofovir, emtricitabine
Name of Non Investigational Medicinal Product : NA
Name of Active Ingredients: NA
Phase of Study: Phase IV
Objectives: The objectives of this study are:
Primary objectives
* To describe prevalence pattern, in patients without self-perceived CNS symptoms related to tenofovir/emtricitabine/efavirenz, of the following parameters assessed at baseline:
* Objective neurocognitive function testing.
* Self-reported central nervous system symptoms by questionnaire
* Reported Sleep quality Secondary objectives
* change in measured neurocognitive parameters from baseline to week 4 and 24
* change in sleep scores from baseline to week 4 and 24
* change in symptoms related to CNS toxicity from baseline over 24 weeks
* change in magnetic resonance imaging (MRI) and spectroscopy of brain between baseline and week 24.
* the rate of maintained virological suppression at \<50 copies/ml at each visit over 24 weeks
* changes in fasting lipids from baseline over 24 weeks
* change in reported adherence from baseline and to week 24 in:
* adherence
* Quality of life
* Reported anxiety and depression
Study Design: Multi-centre, open-label, single pilot study of 24 weeks. Study visits will take place at screening, baseline (within 36 days of screening visit), weeks 4, 12 and 24.
Substudy of 10 volunteers - MRI scan at baseline and week 24
Indication: HIV-1-infection
Methodology:
* Neurocognitive function testing measured by computerised tasks.
* CNS symptoms and sleep quality determined by questionnaire.
* Changes in CNS metabolites by 1H-MR spectroscopy imaging.
Planned Sample Size: 40 (across 4 centres)
Summary of Eligibility Criteria: HIV-infected individuals on Atripla with a viral load \< 50 copies/mL and a CD4 count \> 50 cells/mm3.
Number of Study Centres: 4
Duration of Treatment: 24 weeks
Dose and Route of Administration: A single-pill fixed dose combination of tenofovir 245mg, emtricitabine 200mg and rilpivirine 25mg once daily.
Primary Endpoint: Summary of overall prevalence and categorised descriptions of the following measures will be determined at baseline:
* Neurocognitive function scores calculated as composite scores and individual domains.
* Reported CNS symptoms assessed using questionnaire based on Summary of Product Characteristics (SPC) will be scored for severity and reported as both individual and composite scores.
* Sleep Quality assessed by questionnaire at baseline.
Secondary Endpoint:
* change in measured neurocognitive parameters from baseline to week 4 and 24
* change in sleep scores from baseline to week 4 and 24
* change in symptoms related to CNS toxicity from baseline over 24 weeks
* Change in magnetic resonance imaging and spectroscopy of brain between baseline and week 24.
* the rate of maintained virological suppression at \<50 copies/ml at each visit over 24 weeks
* changes in fasting lipids from baseline over 24 weeks
* change in reported adherence from baseline and to week 24 in:
* adherence
* Quality of life
* Reported anxiety and depression
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Switch from Atripla to Eviplera
Eviplera
A single-pill fixed dose combination of tenofovir 245mg, emtricitabine 200mg and rilpivirine 25mg once daily for 24 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Eviplera
A single-pill fixed dose combination of tenofovir 245mg, emtricitabine 200mg and rilpivirine 25mg once daily for 24 weeks.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Is male or female aged 18 years or above
2. Has HIV-1 infection documented in their medical notes
3. Has signed the Informed Consent Form voluntarily
4. Is willing to comply with the protocol requirements
5. Has been on Atripla for at least 12 weeks before enrolment
6. Has an undetectable HIV-plasma viral load at screening by local assay (single re-test allowed)
7. Has a CD4 cell count at screening \>50 cells/mm3
8. Has an estimated glomerular filtration rate (MDRD) \>50 ml/min.
9. Has no significant CNS symptoms which may be attributable to EFV.
10. If female and of childbearing potential, is using effective birth control methods (for example, hormonal contraceptive, condom, abstinence, IUD, as agreed by the investigator) and is willing to continue practising these birth control methods during the trial and for at least 30 days after the end of the trial. Note: Women who are postmenopausal for least 2 years, women with total hysterectomy, and women who have a tubal ligation are considered of non-childbearing potential
11. If a heterosexually active male, he is using effective birth control methods and is willing to continue practising these birth control methods during the trial and until follow-up visit
Exclusion Criteria
1. Infected with HIV-2
2. Using any concomitant therapy disallowed as per SPC for the study drugs (e.g proton pump inhibitors )
3. Has acute viral hepatitis including, but not limited to, A, B, or C
4. Has chronic hepatitis B and/or C with AST and/or ALT \>5 x ULN Note: Patients can enter trial with chronic HBV if HBV-DNA undetectable at screen (and no detectable result in last 6 months) and with chronic HCV if not expected to require treatment during the trial period.
5. Any investigational drug within 30 days prior to the trial drug administration
6. Has ever received rilpivirine in the past
7. Any clinical evidence of baseline resistance mutations, prior to commencing antiretroviral therapy.
8. Known allergy to lactose monohydrate, sunset yellow aluminium lake (E110), and patients with galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption
9. Severe hepatic impairment (defined as Child-Pugh-Turcotte (CPT) Score C).
10. If female, she is pregnant or breastfeeding
11. Screening blood result with any grade 3/4 toxicity according to Division of AIDS (DAIDS) grading scale, except: asymptomatic grade 3 glucose, amylase or lipid elevation or asymptomatic grade 4 triglyceride elevation (re-test allowed).
12. Any condition (including drug/alcohol abuse) or laboratory results which, in the investigator's opinion, interfere with assessments or completion of the trial.
13. If participating in the MR Imaging substudy, any contraindications to magnetic resonance scanning according to local radiology guidelines (to be assessed by MR Spectroscopy Imaging Department)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gilead Sciences
INDUSTRY
St Stephens Aids Trust
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mark Nelson
Role: PRINCIPAL_INVESTIGATOR
St Stephen's AIDs Trust
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Brighton & Sussex University Hospitals Nhs Trust
Brighton, , United Kingdom
St. Mary's Hospital
London, , United Kingdom
St. Stephen's Centre
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SSAT058
Identifier Type: -
Identifier Source: org_study_id